Cellular effects induced by 17-β-estradiol to reduce the survival of renal cell carcinoma cells

Sheng-Tang Wu¹, Wei-Chi Ku², Chi-Jung Huang³⁴, Yen-Chieh Wang²⁵, Chih-Ming Lin⁶ and Shao-Kuan Chen²⁵*

Abstract

Background: Renal cell carcinoma (RCC) is an adult malignancy with 2:1 men-to-women ratio, which implies the possible role of sex hormones in RCC carcinogenesis. One of the predominant sex hormones in women before menopause, 17-β-estradiol (or E2), may regulate RCC growth by cellular mechanisms that are still not fully understood.

Methods: The expression levels of E2 receptors (ER1 and ER2) were determined in different RCC cell lines. The DNA damage response induced by E2 was determined by a DNA double-strand break marker γH2AX. To study the possible effect of E2 on oxidative stress response, RCC cells were stained with 2,7-dichlorofluorescein diacetate and analyzed by flow cytometry. Upregulation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) ser40 phosphorylation in response to oxidative stress was detected by immunoblotting. Finally, annexin V/propidium iodide (PI) double staining assay was used to determine E2-induced cellular apoptosis.

Results: Variable expression of ER1 and ER2 were found in the RCC cell lines studied (786-O, A498, and ACHN), in which ACHN and A498 showed highest and lowest ER expression, respectively. In A498 cells, E2 induced DNA double-strand breaks with positive staining of γH2AX. On the other hand, the level of reactive oxidative species were elevated in ACHN cells after E2 treatment. The E2-induced oxidative stress also induced the Ser40 phosphorylation and nuclear translocation of Nrf2. Finally, we also demonstrated that E2 induced apoptosis as revealed by annexin V/PI double staining.

Conclusions: In this study, we demonstrated the cellular effects of E2 on DNA repair, ROS production as well as Nrf2 activation, and apoptosis in RCC cell lines. Together these cellular alterations may contribute to the reduced viability of RCC cells following E2 treatment.

Keywords: Renal cell carcinoma, 17-β-estradiol, Estrogen receptors, Oxidative stress, DNA damage

Abbreviations: DCFH-DA, 2′,7′-dichlorofluorescein diacetate; E2, 17-β-estradiol; ER1, E2 receptor 1; ER2, E2 receptor 2; Nrf2, Nuclear factor (erythroid-derived 2)-like 2; RCC, Renal cell carcinoma; ROS, Reactive oxygen species; VEGF, Vascular endothelial growth factor

* Correspondence: skchencmri@gmail.com
¹School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
²Department of Surgery, Sijhih Cathay General Hospital, No. 2, Ln. 59, Jiancheng Rd., Sijhih Dist., New Taipei 22174, Taiwan
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Renal cell carcinoma (RCC) is the most common solid neoplasm of the kidney in adult human. This kidney cancer exhibits a 2:1 male-to-female ratio with a better survival rate in younger women [16]. Thus, there appear to be hormonal effects on the development, progression, and treatment of RCC [31, 33].

In RCC, altered chemosensitivity mediated by 17-β-estradiol (E2) has been reported, so adjuvant therapy with E2 is possible as in other human diseases [24, 45]. The molecular mechanisms of the action of E2 in RCC cells have been reported in recent years [8, 10, 13, 43, 45]. However, diverse genetic alterations are linked to renal cancer progression and to our ability to predict its risk [13, 23]. Targeted therapies incorporating inhibitors of the vascular endothelial growth factor (VEGF) pathway is the major treatment for patients with metastatic RCC [18, 20, 49]. For example, anti-angiogenic drugs such as sunitinib can nullify alterations in the microvascular properties of some human cancers [35]. This inhibition reduces tumor vascularization, and leads to tumor shrinkage. Clinically, cellular adaptations to VEGF-targeted anti-angiogenic therapy might induce drug resistance in RCC after transient disease stabilization, which limits the therapeutic efficacy of this approach and has been the major problem for this treatment. Therefore, a rational and efficacious treatment regimen for treating patients with RCC is needed [4, 14].

E2, is known to exert a protective effect beyond its classical endocrine role in several malignant diseases including neurodegenerative disorders, esophageal cancers, colorectal cancers, lung injuries, and coronary artery diseases [11, 40, 42, 46]. Many cellular functions can be improved by treatment with E2 alone or in combination with its receptors [3, 25]. For example, E2 can induce an increase in sensitivity to oxidative DNA damage through an ER-dependent pathway [28]. Moreover, the oxidative stress has been shown to correlate to phosphorylation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) at Ser40 (phospho S40) in different RCC cell lines (T47-D and MCF-7) gifted from Prof. Shih-Ming Wu (Department of Pediatrics, College of Medicine, National Taiwan University, Taichung, Taiwan). Their genetic characteristics are known from previous reports [9, 47]. In experiments that involved treatment with a specific chemical agent (or target hormone), subconfluent cell cultures were incubated with the indicated concentrations of E2 (E8875, Merck, Darmstadt, Germany) for the indicated times as our previous report [8]. Control cells were treated only with the solvent dimethyl sulfoxide (DMSO).

Immunodetection of estrogen receptors and Nrf2 from RCC cells
The protein levels of two estrogen receptors (ERs), ER1 and ER2, in RCC cells were determined by western blot analysis. For this, protein extracts of each RCC cell line were prepared with Prepar Protein Extraction Solution (iNtRON Biotechnology, Seongnam, South Korea) according to the manufacturer's instructions. Each protein concentration was determined using a BCA Protein Assay (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions. When performing western blotting, protein lysates were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride (PVDF) membranes. Then, each PVDF membrane was incubated with primary antibodies (anti-ER1, ab37438 and anti-ER2, ab3576; both from Abcam, Cambridge, MA, USA) at room temperature. Target signals were exposed and enhanced using Western Lightning Plus-ECL Enhanced Luminol reagent (PK-NEL105, PerkinElmer, Waltham, MA, USA). In addition, the total Nrf2 and its phosphorylated form at Ser40 (phospho S40) in different cellular compartments were determined using specific antibody (ab62352 and ab76026, respectively; Abcam) from 10 µg aliquots of individual proteins. Target signals were amplified using the VECTAStain ABC-AmP kit (AK-6602, Vector Laboratories, Burlingame, CA, USA). The level of glyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH antibody; AM4300, Life Technologies, Carlsbad, CA, USA) was determined as a loading control for whole-cell lysates. An anti-α-tubulin antibody (sc-5286, Santa Cruz Biochemicals, Dallas, TX, USA) was used as an internal control for cytoplasmic protein levels, and lamin A/C (anti-lamin A/C antibody; sc-7292, Santa Cruz Biochemicals) was used as an internal control for nuclear protein levels. Images of immunoblots were captured using a FluorChem FC2 system (Alpha Innotech, Santa Clara, CA, USA). Cell lysates of two breast cancer cell lines (T47-D and MCF-7) gifted from Prof. Shih-Ming

Methods
Cell culture and genetic characteristics of RCC cell lines
The incubation condition and clinical status of three RCC cell lines (ACHN, 786-O, and A498) were based on information disclosed on the website (https://www.atcc.org) of the American Type Culture Collection (Manassas, VA, USA). Their genetic characteristics are known from previous reports [9, 47]. In experiments that involved treatment with a specific chemical agent (or target hormone),...
Huang (Department and Graduate Institute of Biochemistry, National Defense Medical Center, Taiwan) served as positive controls for ER1 and ER2.

Assay for the formation of phosphorylated histone H2AX (γ-H2AX) foci
After incubation for 24 h of 5×10^4 cells per well, DNA double strand breaks (DSBs) were induced in A498 cells using etoposide as described in our previous report [17] and observed in the presence or absence of E2. The ability to repair DSBs was determined by staining with an anti-γ-H2AX antibody using an OxiSelect DNA Double Strand Break Staining Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s instructions with some minor changes. Briefly, cells were allowed to recover by removing the DSB inducer for the indicated time; the exposed DSBs (shown as γ-H2AX foci) appeared as green fluorescence and nuclei were counterstained with 4′,6-diamidino-2-phenylindole. These fluorescent images were all detected using an Olympus IX70 fluorescence microscope (Olympus, Tokyo, Japan).

Detection of intracellular oxidative stress by flow cytometry
Intracellular oxidative stress induced by E2 treatment was determined by flow cytometry using 2′,7′-dichlorofluorescein-diacetate (DCFH-DA) as a sensitive nonfluorescent precursor dye according to a published standard procedure [1]. Cells were seeded on 6-well plates at 1.25×10^5 cells per well and cultured overnight as our previous report and observed in the presence or absence of E2. The ability to repair DSBs was determined by staining with an anti-γ-H2AX antibody using an OxiSelect DNA Double Strand Break Staining Kit (Cell Biolabs, San Diego, CA, USA) according to the manufacturer’s instructions with some minor changes. Briefly, cells were allowed to recover by removing the DSB inducer for the indicated time; the exposed DSBs (shown as γ-H2AX foci) appeared as green fluorescence and nuclei were counterstained with 4′,6-diamidino-2-phenylindole. These fluorescent images were all detected using an Olympus IX70 fluorescence microscope (Olympus, Tokyo, Japan).

Results
Diverse expression levels of ERs in different RCC cell lines
Three RCC cell lines (ACHN, 786-O, and A498) were cultured to detect the expression levels of ER1 and ER2 by western blot analysis (Fig. 1). Among these three cell lines, ACHN cells expressed the highest protein levels of ERs and A498 had the lowest expression, as reported previously for mRNA levels [8]. Therefore, these two RCC cell lines were subsequently analyzed for following cellular effects.

Induction of DNA repair by E2 in A498 cells
A498 cells (low expressions of ERs, wild-type p53, and VHL-null) had different properties of DNA repair under E2 treatment. As shown in Fig. 2, over 90% (37 of 40) cells with active DNA repair were observed with green fluorescence for γH2AX under E2 treatment; whereas, less percentage of cells (44 ,18 of 41) showed fluorescence-positive in the etoposide-treated group. This indicated that E2 could improve DNA repair, even though this RCC cell line had low expression levels of the ERs.

Induction of oxidative stress by E2 in ACHN cells
Reactive oxygen species (ROS), known to reflect oxidative stress, can cause significant damage to cell structures [33]. E2-induced ROS levels in ACHN cells (high ERs, wild-type p53, and VHL-positive) were detected using the DCFH-DA probe. As shown in Fig. 3, ACHN cells showed an increased trend in intracellular ROS levels when cells were treated with E2 (28 μM) for 24 h compared with the DMSO-treated negative control cells.

Detection of apoptosis
To identify apoptosis-positive cells, cells were stained with an Annexin V/propidium iodide (PI) double staining assay, with a fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit I (BD Biosciences), according to the manufacturer’s protocol. Cells with various treatments were washed with buffer (20 mM Tris pH 7.4, 150 mM NaCl, 1 mM CaCl₂) after incubation for 15 min in binding buffer containing 5 μL of Annexin V–FITC and 5 μL of PI at room temperature in the dark. Finally, fluorescent images of Annexin V–FITC binding and PI incorporation were detected using the previous fluorescence microscope.
In addition, activation of the Nrf2 transcription factor was observed (Fig. 4). Briefly, increased phosphorylation of nuclear Nrf2 (1.3 folds, in comparing to the cells treated with DMSO only) were detected in ACHN cells treated with E2 (28 μM), using immunoblot analysis.

**Augmentation of apoptosis by E2 in ACHN cells**

We next analyzed the apoptotic effects of E2 in ACHN cells by detecting Annexin V-positive cells. As shown in Fig. 5, ACHN cells treated with E2 (28 μM) could induce the higher binding rates (70 %, 7 of 10 E2 (10 nM)- and 75 %, 3 of 4 E2 (28 μM)-treated cells) of Annexin V to phosphatidyl serine at the surface of each cell. Conversely, only 10 % (2 of 20) cells shown Annexin V-positive in the DMSO-treated control group.

**Discussion**

Although the number of approved treatments for patients with advanced RCC continues to grow, additional work is still needed to delineate the optimal target drug or combination of agents for each subtype of this cancer [36]. The therapeutic management of RCC is mainly guided by the cancer stage and the degree of tumor dissemination, which affect the prognosis for patients directly [7].Regardless of the clinic availability of the novel targeted therapeutics, and the favorable outcomes, however, complete or durable responses have been only rarely noted. Nearly all treated patients even now will develop drug resistance to any targeted treatment. Approximately 70 % of patients respond to therapy initially and the remaining 30 % show primary resistance (intrinsic resistance) [6, 15]. The 70 % of patients who show...
initial response, durable responses are rare, and acquired resistance (extrinsic resistance) to treatment develops in almost all of them in a median of 6–15 months [6, 15, 32]. However, it remains a challenge in the effective treatment of RCC and suggests that effective therapies for RCC need to be improved [12].

Autophagy mediated by E2 might have inhibited the growth rate of ACHN cells in the present study [8]. In addition, the activities of ERs have been correlated with those of VHL and p53 in many studies [2, 19, 41]. Therefore, the genetic status of VHL and p53 expressions of RCC cells should be considered when E2 is applied to treat RCC. p53-mediated transcription pathways are involved in ER-related pathways [26]. Loss of VHL may attenuate the DNA-damage response and result in the persistence of DSBs [27]. In the present results, A498 cells expressing wild-type p53 but with no VHL expression could repair etoposide-induced DNA damage in the presence of E2. The increased numbers of γH2AX-positive A498 cells implied that lower levels of ERs would not decrease their DNA repair capacity and that E2 treatment could facilitate repair of the DNA breaks even the cells were in the absence of VHL expression. This was similar to the conclusions of other authors who reported that complexes of E2 with ER1 or ER2 modulated the expression of many genes, including those involved in DNA repair [3, 22, 25, 39]. Moreover, the decreased DSBs would be obvious in the ACHN cells with wild type VHL expression. Here, we also found that ACHN cells expressed high levels of ERs. This might indicate that ACHN cells might be sensitive to E2 treatment and that this could induce many other cellular effects. This perspective also arose in other reports showing that E2 might be correlated to the development of this cancer [40, 45].

The highly conserved mechanism of autophagy is essential when cells are under stress, including that induced by ROS [44]. We reported previously that autophagosomes were observed in ACHN cells in the presence of E2 [8]. Sobočanec et al. and Zhu et al. recently reported that E2 could mediate some antioxidant enzymes via the Nrf2–Keap1 pathway [37, 48]. It will be agreed with our data which demonstrate an increased ROS under the E2 treatment. Here, we found that E2 could induce ROS production in ACHN cells. These E2-induced ROS might activate the Nrf2 pathway to reduce the oxidative stress and induce genotoxicity [30, 38]. Subsequently, sequential cell responses, autophagy, and apoptosis changed the fate of the ACHN cells. These findings were confirmed by the expression of activated nuclear Nrf2, a key transcription factor that regulates antioxidant defenses [21]. We found increased phosphorylation of Nrf2 in the nuclei of E2-treated ACHN cells, which might cause a delay in proliferation and induce apoptosis, similar to other cancers [34]. Taken together, our results indicate that Nrf2 activation may be necessary for this E2-induced autophagy and apoptosis. Combination therapy with E2 and target therapeutic agents may be a safe and potential practice clinically to improve the tolerance and treatment duration of target therapy.

Conclusions
Adjuvant therapy with sex hormones could be beneficial in many human diseases [8, 24]. Here, we demonstrated the cellular effects of E2 on DNA repair, ROS production as well as Nrf2 activation, and apoptosis in RCC cell lines. It implies that these cellular alterations may contribute to the reduced viability of RCC cells following E2 treatment.

Acknowledgments
The authors thank Ms. Hsiao-Ting Tseng for her technical support.

Funding
The work was supported by grants from Cathay General Hospital (CGH-MR-10203 to SKC and 102-CGH-FJU-18 to WCK), Fu Jen Catholic University (A0104028 to WCK), and Ministry of Science and Technology (NSC 102-2320-B-030-012-MY2 to WCK).

Availability of data and materials
https://drive.google.com/open?id=0B1QtbaZpq7Fqb3dGd1NOVTdvNUU.

Authors’ contributions
STW, CJH, WCK and SKC designed research. STW, CJH, and SKC performed research. CJH, YCW, and CML analyzed data. STW, WCK, CJH, and SKC wrote paper. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.
References

1. Ashida S, Nishimori I, Tanimura M, Onishi S, Shuin T. Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma. J Cancer Res Clin Oncol. 2002;128(10):561–8.

2. Bado I, Nikols F, Rajapaks G, Gustafsson JA, Thomas C. EHFbeta decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget. 2016;7(12):13595–611.

3. Boland R, Vasconsuelo A, Villanes I, Ronda AC, de Boland AR. 17-beta-estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids. 2008;73(9):859–63.

4. Bridgeman VL, Wan E, Foo S, Nathan MR, Welti JC, Fentans T, Vermeulen PB, Preece N, Springer CJ, Powles T, Nathan PD, Larkin J, Gore M, Vassudev NS, Reynolds AR. Preclinical evidence that tamoxifen enhances the response to antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma. Mol Cancer Ther. 2016;15(1):172–83.

5. Buehna-Chontal M, Guevara-Chavez JG, Silva-Palacios A, Medina-Campos ON, Pedraza-Chaverri J, Zazueta C. Nrf2-regulated antioxidant response is activated by protein kinase C in postconditioned rat hearts. Free Radic Biol Med. 2014;74:145–56.

6. Busch J, Seidel C, Weikert S, Wolff I, Kempkensteen C, Weinkauf L, Hinz S, Busch J, Seidel C, Weikert S, Wolff I, Kempkensteen C, Weinkauf L, Hinz S, Maghelli A, Miller K, Grunwald V. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11:295.

7. Chen DY, Uzzo RG. Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance? J Natl Compr Canc Netw. 2009;7(6):635–42. quiz 643.

8. Chen KC, Lim CM, Huang CJ, Chen SK, Wu ST, Chiang HS, Ku WC. Dual roles of 17-beta estradiol in estrogen receptor-dependent growth inhibition in renal cell carcinoma. Cancer Genomics Proteomics. 2016;13(3):219–29.

9. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Maghelli A, Miller K, Grunwald V. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. Mol Cancer Ther. 2016;15(1):172–83.

10. Czarnecka AM, Niedzwiedzka M, Porta C, Szczylik C. Hormone signaling developments. Curr Oncol Rep. 2012;14(3):240–9.

11. D'Alessandro A, D'Aguzzino S, Cencioni MT, Pieroni L, Diamantini A, Battistini L, Longone P, Spalloni A, De Laurentis V, Bernardini S, Fedegici G, Urbani A. Protein repertoire impact of Ubiquitin-Proteasome System impairment: insight into the protective role of beta-estradiol. J Proteomics. 2012;75(4):1440–53.

12. Farber LJ, Furge K, Teh BT. Renal cell carcinoma deep sequencing: recent developments. Curr Oncol Rep. 2012;14(3):240–8.

13. Feng C, Xiong Z, Jiang H, Ding Q, Fang Z, Hui W. Genetic alteration in notch pathway is associated with better prognosis in renal cell carcinoma. BioFactors. 2016;42(1):1–8.

14. Han KS, Raven PA, Frees S, Gust K, Fazli L, Ettinger S, Hong SJ, Kollmannsberger C, Gleave ME. So AI. Celluluar adaptation to VEGF-targeted antiangiogenic therapy induces evasive resistance by overproduction of alternative endothelial cell growth factors in renal cell carcinoma. Neoplasia. 2015; 17(1):805–16.

15. Heng DY, Mackenzie MJ, Vashishpayyan UN, Bjarnason GA, Knox JJ, Tan MH, Wood L, Wang Y, Kollmannsberger C, North S, Donskov F, Rini BI, Choueiri TK. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Ann Oncol. 2012;23(6):1549–55.

16. Hew MN, Zonneveld R, Kummerl IP, Opondo D, de la Rosette JJ, Laguna AP. Age and gender related differences in renal cell carcinoma in a European cohort. J Urol. 2012;188(1):33–8.

17. Huang CJ, Yang SH, Lee CL, Cheng YC, Tai SY, Chien CC. Ribosomal protein S22-like in colorectal cancer: a candidate for predicting prognoses. PLoS One. 2013(8)(6):e67043.

18. Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016; 388(10043):518–29.

19. Jung YS, Chun HY, Yoon MH, Park BJ. Elevated estrogen receptor-alpha in VHL-deficient condition induces microtubule organizing center amplification via disruption of BRCAl/Rad51 interaction. Neoplasia. 2014;16(12):1070–81.

20. Kaymakcalan MD, Xie W, Albiliges L, North SA, Kollmannsberger CK, Smiragulovitz M, Kroeger N, Wells J, JCA, Rha SY, Lee JL, McKay RR, Fay AP, De Velasco G, Heng DY, Choueiri TK. Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2016;122(3):411–9.

21. Li N, Alam J, Venkatesan MI, Eiguren-Fernandez A, Schmitz D, Di Stefano E, Slaughter N, Killeen E, Wang X, Huang A. Nrf2 is a key transcription factor that regulates antioxidant defense in macrophages and epithelial cells, protecting against the proinflammatory and oxidizing effects of diesel exhaust chemicals. J Immunol. 2004;173(5):3467–81.

22. Lin CY, Strom A, Vega VB, Kong SI, Yeo AL, Thomsen JS, Chan DH, Doray B, Bangararamy DK, Rama Ramay A, Vargara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET. Discovery of estrogen receptor alpha target genes and response elements in breast tumor genomes. Genome Biol. 2004;5(9):R66.

23. Loganow VJ, Dmitriev AA, Senchenko VN, Pronina N, Khodyrev DS, Kudryavsteva AV, Krasnov GS, Gerashchenkov GV, Chashchina LI, Kazubskaya TP, Kondratieva TT, Lerman M, Angeloni D, Braga EA, Kashuba VI. Tumor suppressor function of the SEMA3B gene in human lung and renal cancers. PLoS One. 2015;10(5):10(5):e0123369.

24. Maxow DE, Roach EC, Beauregard KG, Khalil R. A. Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab. 2010;11(8):693–714.

25. Mateos L, Persson T, Kallio S, Gil-Bea FJ, Cezado-Miguez A. Estrogen protects against amyloid-β toxicity by estrogen receptor α-mediated inhibition of Daxx translocation. Neurosci Lett. 2012;506(2):245–50.

26. Menendez D, Inga A, Resnick MA. Estrogen receptor acting in cis enhances WT and mutant p53 transactivation at canonical and noncanonical p53 target sequences. Proc Natl Acad Sci. 2010;107(4):1500–5.

27. Metczal JL, Bradshaw PS, Kornosa M, Greer SN, Meyer M, Morey M. KeS-ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair. Oncogene. 2014;33(8):1055–65.

28. Moobley JB, Brauggeerrie RV. Estrogen receptor-mediated regulation of oxidative stress and DNA damage in breast cancer. Carcinogenesis. 2004;25(1):13–9.

29. Mota S, Costa RO, Ferreira IL, Santana I, Caldeira GL, Padovano C, Fonseca AC, Baldeiras I, Cunha C, Letto L, Oliveira CR, Pereira CM, Rego AC. Oxidative stress involving changes in Nf2 and ER stress in early stages of Alzheimer’s disease. Biochim Biophys Acta. 2015;1852(7):1428–41.

30. Okoh V, Deoraj A, Roy D. Estrogen-induced reactive oxygen species-mediated signaling contributions to breast cancer. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2011;1815(1):115–33.

31. Rampersaud EN, Klute T, Bati G, Patard JI, Bansal K, Bohm M, Alloph EP, Cindolo L, De La Taille A, Mejean A, Soulie M, Bellec L, Christophe Bernhard J, Pfister C, Colombo M, Belledurgeon AS, Pantuck AJ, George D. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma. Urol Oncol. 2014;32(1):309–13.

32. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. The Lancet Oncology. 2009;10(10):992–1000.

33. Roy D, Cai Q, Felty Q, Narayan S. Estrogen-induced generation of reactive oxygen and nitrogen species, gene damage, and estrogen-dependent cancers. J Toxicol Environ Health B Crit Rev. 2007;10(4):235–57.

34. Schafer G, H Kaschula C. The immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anticancer Agents Med Chem. 2014;14(2):233–40.
35. Schroeder M, Viezens L, Wellbrock J, Fiedler W, Ruther W, Algenstaedt P, Hansen-Algenstaedt N, Schaefer C. Sunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone. J Surg Oncol. 2016;113(5):515–21.

36. Singer EA, Gupta GN, Marchalik D, Sinivasan R. Evolving therapeutic targets in renal cell carcinoma. Curr Opin Oncol. 2013;25(3):273–80.

37. Sobocanec S, Saric A, Macak Safranko Z, Popovic Hadzija M, Abramic M, Balog T. The role of 17beta-estradiol in the regulation of antioxidant enzymes via the Nrf2-Keap1 pathway in the livers of CBA/H mice. Life Sci. 2015;130:57–65.

38. To C, Ringelberg CS, Royce DB, Williams CR, Sporn MB, Liby KT. Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesis. Carcinogenesis. 2015;36(7):769–81.

39. Vasconsuelo A, Milanesi L, Boland R. 17beta-estradiol abrogates apoptosis in murine skeletal muscle cells through estrogen receptors: role of the phosphatidylinositol 3-kinase/Akt pathway. J Endocrinol. 2008;196(2):385–97.

40. Wang QM, Qi YJ, Jiang Q, Ma YF, Wang LD. Relevance of serum estradiol and estrogen receptor beta expression from a high-incidence area for esophageal squamous cell carcinoma in China. Med Oncol. 2011;28(1):188–93.

41. Wang X, Simpson ER, Brown KA. p53: protection against tumor growth beyond effects on cell cycle and apoptosis. Cancer Res. 2015;75(23):5001–7.

42. Weige CC, Alred KE, Alred CD. Estriol alters cell growth in nonmalignant colonocytes and reduces the formation of preneoplastic lesions in the colon. Cancer Res. 2009;69(23):9118–24.

43. Weng WH, Chen YT, Yu KJ, Chang YH, Chuang CK, Pang ST. Genetic alterations of HER genes in chromophobe renal cell carcinoma. Oncol Lett. 2016;11(3):2111–6.

44. Wu JJ, Quijano C, Chen E, Liu H, Cao L, Fergusson MM, Rovira II, Gutkind S, Daniel MP, Komatsu M, Finkel T. Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging (Albany NY). 2009;1(4):425–37.

45. Yu CP, Ho JY, Huang YT, Cha TL, Sun GH, Yu DS, Chang FW, Chen SP, Hsu RJ. Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-beta activation. PLoS One. 2013;8(2):e56667.

46. Yu GS, Lai CY, Xu Y, Bu CF, Su ZX. Aberrant methylation of RASSF1A gene contribute to the risk of renal cell carcinoma: a meta-analysis. Asian Pac J Cancer Prev. 2015;16(11):4665–9.

47. Yuan J, Luo K, Zhang L, Cheville JC, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140(3):384–96.

48. Zhu C, Wang S, Wang B, Du F, Hu C, Li H, Feng Y, Zhu R, Mo M, Cao Y, Li A, Yu X. 17beta-Estradiol up-regulates Nrf2 via PI3K/AKT and estrogen receptor signaling pathways to suppress light-induced degeneration in rat retina. Neuroscience. 2015;304:328–39.

49. Zisman A, Patard JJ, Raz O, Haifler M, Mendlovic S, Sandbank J, Beldeגרun AS, Lindner A, Leibovici D, Pantuck AJ. Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings: a multicenter survey. Urology. 2010;76(3):341–6.